Future perspectives for acute promyelocytic leukemia therapy.
Acute promyelocytic leukemia (APL) is the first leukemia where targeted therapy proved to be effective, as only patients with retinoic acid-sensitive APL leukemic-clones responded in vivo. The future perspectives of APL therapy should persist in targeting either the APL's cell-specific characteristics concerning differentiation, cell cycle, and survival potentials, or the molecular markers specific to the APL clone. Converging recent advances in cellular therapy and in scientific concepts of cell differentiation should aim toward a possible cure of APL.
Cassinat
B
B
H pital Saint-Louis, Laboratoire de Biologie Cellulaire Hématopoiétique, Paris, France.
Chomienne
C
C
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000187:drug effects; D016503:Drug Delivery Systems / Q000639:trends; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*
D000970:Antineoplastic Agents